Commentary

Ageusia, A Highly Specific Symptom of COVID-19, for Which an Unaware Patient May Seek Dental Assistance

The rapid worldwide spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has profoundly changed dental practice with the initial suspension of all clinical activities except emergent situations. In Europe, many countries are moving toward the so-called ‘phase 2’, coexistence with the virus. Of course, the resumption of activities will cause a rise in the contagion curve. To slow this rise in cases, it will be essential to be able to identify suspicious cases and to ensure that such patients undergo a nasopharyngeal swab. A knowledge of the most frequent symptoms in the early stages of coronavirus disease 2019 (COVID-19) is mandatory to achieve this goal and dentists, through the anamnestic information collected during the triage procedures, will have a fundamental role in this process.

Taste and smell disturbances were reported as rare findings in these patients, in the Chinese case series, affecting only 5% of patients.1 At the end of March, we first realised that in Italian COVID-19 patients the incidence of these conditions was much higher, and, in particular, these symptoms were very frequent in the early stages of the disease.2,3 Subsequently, similar findings have been reported by several authors in Europe and America,4−6 with incidences of around 70% of these patients. Chemosensitive disorders represent early symptoms of COVID-19, commonly occurring within 2−3 days after the clinical onset.7−9 The latest data reported by Petrocelli et al.,4 evaluating the gustatory function in 300 patients in the first 4 days from the clinical onset, detected a taste dysfunction in 60.4% of the cases. Interestingly, in a large multicentre Italian study recently published by our group, chemosensitive symptoms proved to be the first symptom of COVID-19 in 29.2% of patients and the only one in 9.5% of cases.9 In most patients, the recovery of gustatory function generally occurs within 3 weeks. However, in 7.2% of cases, severe ageusia or hypogeusia can persist for more than 60 days.10

The pathogenesis of these disorders is probably related to the infection of the support cells to the olfactory and gustatory receptors, rich in angiotensin converting enzyme 2 (ACE2) receptors.11 In fact, ageusia is a well-known side effect of ACE2-inhibitors.

Ageusia is a rare condition that is characterised by a complete loss of taste function of the tongue. This condition is one of the typical symptoms of COVID-19 has important implications in dental practice. At the beginning of the epidemic in Italy, an abnormal number of patients attended our dental, neurological and surgical clinics on account of the detection of sudden onset ageusia, not associated with any other symptoms. Subsequently, SARS-CoV-2 infection was soon diagnosed in these patients following the further onset of fever and cough. This strange coincidence was the reason that prompted us to start investigating the role of chemosensitive disorders in COVID-19.

Based on the growing number of reports that place these COVID-19 symptoms as the second most frequent after fever, several countries are including chemosensitive disorders in their guidelines for the diagnosis of SARS-CoV-2 infection.

Dentists should be warned that in respect of patients seeking assistance for the sudden onset of ageusia, a suspicion of ongoing coronavirus infection should be considered in a differential diagnosis. In the same way, chemosensitive disorders should be investigated in the anamnestic data collection during pretriage procedures. If present or recently experienced, the patient should be referred to a COVID-19 hospital for a nasal swab for identification of the virus.

Based on the frequency of these symptoms, which can often be the reason why the patient attends for a dental appointment, we think it is essential that they are included in the dental association national guidelines that will be the issued for the resumption of clinical activity during the post-epidemic era.

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Conflict of interests

None declared.

REFERENCES

1. Mao L, Jin H, Wang M, et al. Neurologic manifestations of hospitalized patients with Coronavirus Disease 2019 in Wuhan, China. JAMA Neurol 2020;77:683.
2. Vaira LA, Salzano G, Deiana G, et al. Ageusia and anosmia: common findings in COVID-19 patients. Laryngoscope 2020;130:1787.
3. Vaira LA, Salzano G, De Riu G. The importance of olfactory and gustatory disorders as early symptoms of coronavirus disease (COVID-19). Br J Oral Maxillofac Surg 2020;58:615–6.
4. Petrocelli M, Ruggiero F, Baietti AM, et al. patients: the Bologna experience of 300 cases. J Laryngol Otol 2020;134:571–6.
5. Lechien JR, Chiesta-Estomba CM, De Siati DR, et al. Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study. Eur Arch Otorhinolaryngol 2020;277:2251–61.

6. Xydakis MS, Dehgani-Mobaraki P, Holbrook EH, et al. Smell and taste dysfunction in patients with COVID-19. Lancet Infect Dis 2020;20:1015–6. doi: 10.1016/S1473-3099(20)30293-0.

7. Vaira LA, Deiana G, Fois AG, et al. Objective evaluation of anosmia and ageusia in COVID-19 patients: a single-center experience on 72 cases. Head Neck 2020;42:1252–8.

8. Vaira LA, Salzano G, Petrocelli M, et al. Validation of a self-administered olfactory and gustatory test for the remotely evaluation of COVID-19 patients in home quarantine. Head Neck 2020;42:1570–6.

9. Vaira LA, Hopkins C, Salzano G, et al. Olfactory and gustatory function impairment in COVID-19 patients: An Italian objective multicenter-study. Head Neck 2020;42:1560–9.

10. Vaira LA, Hopkins C, Petrocelli M, et al. Smell and taste recovery in COVID-19 patients: a 60-day objective and prospective study. J Laryngol Otol 2020;124:1–14.

11. Vaira LA, Salzano G, Fois AF, et al. Potential pathogenesis of ageusia and anosmia in COVID-19 patients. Int Forum Allergy Rhinol 2020;10:1103–4. doi: 10.1002/alr.22593.

Giovanni Salzano
Maxillofacial Surgery Operative Unit,
University Hospital of Naples “Federico II”, Naples, Italy

Fabio Maglitto*
Maxillofacial Surgery Operative Unit,
University Hospital of Naples “Federico II”, Naples, Italy

Luigi Angelo Vaira
Maxillofacial Surgery Unit,
University Hospital of Sassari, Sassari, Italy

Francesco Antonio Salzano
Department of Medicine, Surgery and Dentistry, “Scuola Medica Salernitana”, University of Salerno, Salerno, Italy

Giacomo De Riu
Maxillofacial Surgery Unit,
University Hospital of Sassari, Sassari, Italy

*Corresponding author. Fabio Maglitto, Maxillofacial Department, University of Naples Federico II, Via Pansini 5, 80100 Naples, Italy.

E-mail address: fmaglitto@gmail.com (F. Maglitto).

0020-6539/© 2021 The Authors. Published by Elsevier Inc on behalf of FDI World Dental Federation. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
https://doi.org/10.1111/idj.12620